primary hypopituitarism had no ACTHresponse to CRF. The patients in both groups had no ACTH response to hypoglycemia.This result suggests that the response of the pituitary corticotroph to CRF is preserved after hypothalamic dysfunction.
In patients with Cushing's syndrome of adrenal origin, low ACTHand high cortisol levels did not response to CRF. In Cushing's disease, elevated plasma ACTHand cortisol levels increased after CRF injection.
In patients with ectopic ACTH syndrome, plasma ACTH responses to CRFwere variable. The CRF test also was useful for evaluating the recovery of the HPAaxis after remission of hypercortisolemia. The recovery of cortisol response to CRF(9-12 months) was delayed as compared with that of ACTH (6-9 months).
Lowered levels of CRFin plasma and cerebrospinal fluid returned to the normal range 3-6 months after the remission. L Effects of TRHon limb ataxia of SCD Effects of acute and chronic administration of TRHon ataxia of the upper limbs of SCDpatients were analysed using a position sensor system. Subjects consisted of 12 SCD patients (7 males and 5 females). The age ranged between 46 and 71 years old (average 56.1 years old). Based upon the classification of subtypes of SCD, 2 were Menzel type of olivopontocerebellar atrophy (OPCA), 4 were sporadic OPCA,2 were Shy-Drager syndrome, 2 were striato-nigral degeneration, 1 was dentatorubropallidoluysian atrophy (DRPLA) and 1 was
Joseph's disease.
The patients were instructed to touch a target 0.5m apart in front of them with their index fingers as soon as possible when they heard a trigger sound. The positions of the index finger, wrist, elbow and shoulder were recorded with a position sensor system. The movement was analysed measuring the following indexes. Reaction time (RT) was a period between the trigger sound and the start of the movement. Movement time (MT) was a period between the start and the end of the movement.Touch time (TT) was the sum of RT and MT. Correction time (CT) was a period between the beginning of slow approach of the finger near the target and the end of the movement.Vmaxmeant maximum movement velocity. CP was the movementtrajectory of the index finger during CT, and CDwas the straight distance between the starting point of CTand the end of it. In the previous report, we showedthat RT, MT, CT and CP/CD were larger and Vmax was smaller in SCDpatients than in normal controls. After intravenous administration of 2 mg TRH, RT 2. Effects of oral administration of TRHon ataxia of SCD TRHwas administered orally in a dose of 24mg daily for longer than 6 months to 22 patients with SCD. 15 were males and 7 were females. The age ranged between 31 and 66 years old (average 46.6 years old). Based upon the classification of subtypes of SCD, 1 was late cerebellar cortical atrophy (LCCA), 14 were Menzel type of OPCAand 7 were sporadic OPCA. Ataxia improvement rating of standing, gait, speech and writing and global improvement rating were evaluated at the end of 1, 2, 3, 6, 9, 12, 24, 36 and 48 months of treatment. The result of global improvement rating revealed that responses rated as moderately improved and slightly improved were approximately 10 to 20% between 2 and 12 months after the start of treatment. The rate of the patients rated as moderately aggravated and slightly aggravated were steadily increased after 3 months. More than 30% of patients were rated as no change even at 12 and 24 months after the start of the treatment.
These results seemed to indicate that this drug does not have such effect as improving the ataxic symptoms in SCD for a long period, but has usefulness in preventing the aggravation of the symptoms. 
